Header Logo

Connection

BONNIE S GLISSON to Middle Aged

Back to Details
This is a "connection" page, showing publications BONNIE S GLISSON has written about Middle Aged.
BONNIE S GLISSON
Connection Strength
0.645
Middle Aged
  1. Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 10 15; 26(20):5358-5367.
    View in: PubMed
    Score: 0.027
  2. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. J Thorac Oncol. 2020 02; 15(2):266-273.
    View in: PubMed
    Score: 0.026
  3. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):67-73.
    View in: PubMed
    Score: 0.024
  4. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. Cancer. 2018 05 15; 124(10):2169-2173.
    View in: PubMed
    Score: 0.023
  5. A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer. Clin Lung Cancer. 2017 11; 18(6):615-625.e8.
    View in: PubMed
    Score: 0.022
  6. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. Cancer. 2010 May 15; 116(10):2409-15.
    View in: PubMed
    Score: 0.013
  7. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006 Sep 01; 24(25):4163-9.
    View in: PubMed
    Score: 0.010
  8. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. Cancer. 2006 Jan 15; 106(2):366-74.
    View in: PubMed
    Score: 0.010
  9. A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2005 Nov 01; 63(3):717-24.
    View in: PubMed
    Score: 0.010
  10. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2024 Oct 23; 12(10).
    View in: PubMed
    Score: 0.009
  11. A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2024 Nov; 25(7):601-611.
    View in: PubMed
    Score: 0.009
  12. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. Leuk Res. 2004 Jun; 28(6):657-60.
    View in: PubMed
    Score: 0.009
  13. Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors. Cancer. 2004 May 15; 100(10):2240-5.
    View in: PubMed
    Score: 0.009
  14. A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. Cancer. 2004 Mar 01; 100(5):991-8.
    View in: PubMed
    Score: 0.009
  15. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):17-21.
    View in: PubMed
    Score: 0.008
  16. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer. 2003 Jul; 5(1):40-5.
    View in: PubMed
    Score: 0.008
  17. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. Clin Cancer Res. 2003 Jun; 9(6):2085-91.
    View in: PubMed
    Score: 0.008
  18. Direct correlation between FRA3B expression and cigarette smoking. Genes Chromosomes Cancer. 2002 Jul; 34(3):333-40.
    View in: PubMed
    Score: 0.008
  19. Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol. 2002 Mar 15; 20(6):1593-9.
    View in: PubMed
    Score: 0.008
  20. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nat Commun. 2021 11 17; 12(1):6655.
    View in: PubMed
    Score: 0.007
  21. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precis Oncol. 2021 08; 5.
    View in: PubMed
    Score: 0.007
  22. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565.
    View in: PubMed
    Score: 0.007
  23. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
    View in: PubMed
    Score: 0.007
  24. The tumor immune contexture of salivary duct carcinoma. Head Neck. 2021 04; 43(4):1213-1219.
    View in: PubMed
    Score: 0.007
  25. Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. Eur J Cancer. 2021 02; 144:169-177.
    View in: PubMed
    Score: 0.007
  26. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clin Cancer Res. 2021 02 01; 27(3):852-864.
    View in: PubMed
    Score: 0.007
  27. High-grade sinonasal carcinomas and surveillance of differential expression in immune related transcriptome. Ann Diagn Pathol. 2020 Dec; 49:151622.
    View in: PubMed
    Score: 0.007
  28. Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12. J Clin Oncol. 2000 Aug; 18(16):2990-5.
    View in: PubMed
    Score: 0.007
  29. Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg. 2020 02 01; 146(2):128-135.
    View in: PubMed
    Score: 0.007
  30. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. Clin Cancer Res. 2020 02 15; 26(4):892-901.
    View in: PubMed
    Score: 0.006
  31. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. Clin Cancer Res. 2019 12 01; 25(23):6958-6966.
    View in: PubMed
    Score: 0.006
  32. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol. 1999 Aug; 17(8):2309-15.
    View in: PubMed
    Score: 0.006
  33. Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma. Ophthalmic Plast Reconstr Surg. 2019 Jul/Aug; 35(4):350-353.
    View in: PubMed
    Score: 0.006
  34. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2019 03 01; 30(3):471-477.
    View in: PubMed
    Score: 0.006
  35. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 06; 14(6):1021-1031.
    View in: PubMed
    Score: 0.006
  36. Radiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes. Cancer. 2019 05 01; 125(9):1536-1546.
    View in: PubMed
    Score: 0.006
  37. Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma. J Clin Oncol. 2019 02 20; 37(6):504-512.
    View in: PubMed
    Score: 0.006
  38. PI3-kinase pathway biomarkers in oral cancer and tumor immune cells. Head Neck. 2019 03; 41(3):615-622.
    View in: PubMed
    Score: 0.006
  39. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clin Cancer Res. 2018 12 15; 24(24):6195-6203.
    View in: PubMed
    Score: 0.006
  40. Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nat Commun. 2018 08 06; 9(1):3114.
    View in: PubMed
    Score: 0.006
  41. Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma. Br J Ophthalmol. 2019 06; 103(6):775-780.
    View in: PubMed
    Score: 0.006
  42. Phase II trial of recombinant IFN-alpha2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer. J Interferon Cytokine Res. 1998 Apr; 18(4):241-5.
    View in: PubMed
    Score: 0.006
  43. Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma. Head Neck. 2018 08; 40(8):1676-1684.
    View in: PubMed
    Score: 0.006
  44. Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas. Oncologist. 2018 05; 23(5):526-e49.
    View in: PubMed
    Score: 0.006
  45. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma. Cancer. 1998 Jan 15; 82(2):301-8.
    View in: PubMed
    Score: 0.006
  46. Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study. Int J Radiat Oncol Biol Phys. 1998 Jan 15; 40(2):331-6.
    View in: PubMed
    Score: 0.006
  47. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res. 2018 03 01; 24(5):1038-1047.
    View in: PubMed
    Score: 0.006
  48. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial. J Am Acad Dermatol. 2017 Dec; 77(6):1110-1113.e2.
    View in: PubMed
    Score: 0.006
  49. Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Head Neck. 2017 08; 39(8):1671-1679.
    View in: PubMed
    Score: 0.005
  50. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017 01; 18(1):42-51.
    View in: PubMed
    Score: 0.005
  51. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol. 2017 Jan 20; 35(3):352-360.
    View in: PubMed
    Score: 0.005
  52. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 2016 Apr 26; 7(17):23227-38.
    View in: PubMed
    Score: 0.005
  53. Outcomes for hypopharyngeal carcinoma treated with organ-preservation therapy. Head Neck. 2016 04; 38 Suppl 1:E2091-9.
    View in: PubMed
    Score: 0.005
  54. Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas. Head Neck. 2016 04; 38 Suppl 1:E1459-66.
    View in: PubMed
    Score: 0.005
  55. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. 2015 May; 37(5):644-9.
    View in: PubMed
    Score: 0.005
  56. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol. 1995 Mar; 13(3):645-51.
    View in: PubMed
    Score: 0.005
  57. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014 May 21; 311(19):1998-2006.
    View in: PubMed
    Score: 0.004
  58. The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer. Cancer. 2013 Sep 01; 119(17):3162-9.
    View in: PubMed
    Score: 0.004
  59. Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. Radiat Oncol. 2013 Jan 29; 8:21.
    View in: PubMed
    Score: 0.004
  60. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013 Mar 01; 31(7):845-52.
    View in: PubMed
    Score: 0.004
  61. Patterns of disease recurrence following treatment of oropharyngeal cancer with intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):941-7.
    View in: PubMed
    Score: 0.004
  62. An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center: a staging system in need of repair. Cancer. 2013 Jan 01; 119(1):81-9.
    View in: PubMed
    Score: 0.004
  63. Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):e531-6.
    View in: PubMed
    Score: 0.004
  64. Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2012 Mar 01; 82(3):e367-74.
    View in: PubMed
    Score: 0.004
  65. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Mar 01; 18(5):1435-46.
    View in: PubMed
    Score: 0.004
  66. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol. 2012 Feb; 13(2):172-80.
    View in: PubMed
    Score: 0.004
  67. Resectability of small-cell lung cancer following induction chemotherapy in patients with limited disease (stage II-IIIb). Am J Clin Oncol. 1991 Oct; 14(5):427-32.
    View in: PubMed
    Score: 0.004
  68. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer. 2011 May 15; 117(10):2112-9.
    View in: PubMed
    Score: 0.003
  69. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol. 2010 Nov; 5(11):1835-40.
    View in: PubMed
    Score: 0.003
  70. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun; 9(6):1755-63.
    View in: PubMed
    Score: 0.003
  71. Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. Am J Clin Oncol. 2010 Apr; 33(2):148-52.
    View in: PubMed
    Score: 0.003
  72. Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):1005-10.
    View in: PubMed
    Score: 0.003
  73. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010 Jan 01; 28(1):8-14.
    View in: PubMed
    Score: 0.003
  74. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009 Aug 01; 27(22):3684-90.
    View in: PubMed
    Score: 0.003
  75. A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2009 Jun; 32(3):274-9.
    View in: PubMed
    Score: 0.003
  76. Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol. 2009 Apr 20; 27(12):1976-82.
    View in: PubMed
    Score: 0.003
  77. Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study. Cancer. 2008 Jun 15; 112(12):2698-709.
    View in: PubMed
    Score: 0.003
  78. Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):119-27.
    View in: PubMed
    Score: 0.003
  79. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys. 2009 Feb 01; 73(2):399-409.
    View in: PubMed
    Score: 0.003
  80. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer. J Thorac Oncol. 2007 Aug; 2(8):745-50.
    View in: PubMed
    Score: 0.003
  81. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer. 2006 Mar; 7(5):326-31.
    View in: PubMed
    Score: 0.002
  82. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer. 2005 Dec 01; 104(11):2449-56.
    View in: PubMed
    Score: 0.002
  83. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer. 2005 Aug 01; 104(3):561-9.
    View in: PubMed
    Score: 0.002
  84. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys. 2005 Jun 01; 62(2):342-50.
    View in: PubMed
    Score: 0.002
  85. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer. 2004 Dec 01; 101(11):2567-73.
    View in: PubMed
    Score: 0.002
  86. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol. 2004 Jul 15; 22(14):2856-64.
    View in: PubMed
    Score: 0.002
  87. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res. 2004 May 01; 10(9):2968-76.
    View in: PubMed
    Score: 0.002
  88. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer. 2004 Apr; 44(1):99-110.
    View in: PubMed
    Score: 0.002
  89. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1369-77.
    View in: PubMed
    Score: 0.002
  90. Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? Cancer. 2004 Mar 15; 100(6):1171-8.
    View in: PubMed
    Score: 0.002
  91. Management of nonsinonasal neuroendocrine carcinomas of the head and neck. Cancer. 2003 Dec 01; 98(11):2322-8.
    View in: PubMed
    Score: 0.002
  92. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003 Nov 27; 349(22):2091-8.
    View in: PubMed
    Score: 0.002
  93. Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer. 2003 Nov 15; 98(10):2214-23.
    View in: PubMed
    Score: 0.002
  94. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003 Oct; 39(7):724-7.
    View in: PubMed
    Score: 0.002
  95. Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11. Arch Otolaryngol Head Neck Surg. 2003 Jan; 129(1):44-9.
    View in: PubMed
    Score: 0.002
  96. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 2003 Jan; 9(1):93-101.
    View in: PubMed
    Score: 0.002
  97. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer. 2002 Jul 15; 95(2):322-30.
    View in: PubMed
    Score: 0.002
  98. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer. 2002 Jul 15; 95(2):340-53.
    View in: PubMed
    Score: 0.002
  99. A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck. 2002 Jul; 24(7):661-9.
    View in: PubMed
    Score: 0.002
  100. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol. 2002 Jan 15; 20(2):364-70.
    View in: PubMed
    Score: 0.002
  101. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol. 2002 Jan; 12(1 Suppl 1):46-9.
    View in: PubMed
    Score: 0.002
  102. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer. 2001 Dec; 34(3):427-32.
    View in: PubMed
    Score: 0.002
  103. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2001 Nov 01; 92(9):2364-73.
    View in: PubMed
    Score: 0.002
  104. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol. 2001 Jun 15; 19(12):3010-7.
    View in: PubMed
    Score: 0.002
  105. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res. 2001 May; 7(5):1204-13.
    View in: PubMed
    Score: 0.002
  106. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer. 2001 Apr 01; 91(7):1316-23.
    View in: PubMed
    Score: 0.002
  107. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol. 2001 Mar 15; 19(6):1830-8.
    View in: PubMed
    Score: 0.002
  108. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2001 Feb 15; 19(4):1096-104.
    View in: PubMed
    Score: 0.002
  109. Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest New Drugs. 2000 Aug; 18(3):243-5.
    View in: PubMed
    Score: 0.002
  110. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). Cancer Gene Ther. 2000 Apr; 7(4):530-6.
    View in: PubMed
    Score: 0.002
  111. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol. 2000 Feb; 18(3):609-22.
    View in: PubMed
    Score: 0.002
  112. Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses. J Clin Oncol. 1999 Aug; 17(8):2390-5.
    View in: PubMed
    Score: 0.002
  113. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999 May 05; 91(9):763-71.
    View in: PubMed
    Score: 0.002
  114. A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer: a 5-year follow-up report. Int J Radiat Oncol Biol Phys. 1998 Oct 01; 42(3):479-86.
    View in: PubMed
    Score: 0.001
  115. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998 Apr; 16(4):1325-30.
    View in: PubMed
    Score: 0.001
  116. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol. 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8.
    View in: PubMed
    Score: 0.001
  117. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol. 1998 Feb; 16(2):735-44.
    View in: PubMed
    Score: 0.001
  118. Phase I study of paclitaxel administered by ten-day continuous infusion. Invest New Drugs. 1998-1999; 16(3):237-43.
    View in: PubMed
    Score: 0.001
  119. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol. 1997 Dec; 24(6 Suppl 19):S19-33-S19-37.
    View in: PubMed
    Score: 0.001
  120. Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: a preliminary report. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-52-S12-55.
    View in: PubMed
    Score: 0.001
  121. Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma: results of a matched cohort study. Cancer. 1997 Apr 01; 79(7):1279-86.
    View in: PubMed
    Score: 0.001
  122. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol. 1997 Jan; 15(1):310-6.
    View in: PubMed
    Score: 0.001
  123. Does induction chemotherapy have a role in the management of nasopharyngeal carcinoma? Results of treatment in the era of computerized tomography. Int J Radiat Oncol Biol Phys. 1996 Dec 01; 36(5):1005-12.
    View in: PubMed
    Score: 0.001
  124. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol. 1996 Oct; 14(10):2785-90.
    View in: PubMed
    Score: 0.001
  125. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol. 1996 Feb; 14(2):503-13.
    View in: PubMed
    Score: 0.001
  126. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer. Int J Radiat Oncol Biol Phys. 1995 Feb 15; 31(4):807-11.
    View in: PubMed
    Score: 0.001
  127. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol. 1994 Jun; 12(6):1238-44.
    View in: PubMed
    Score: 0.001
  128. Retinoic acid and interferon combination studies in human cancer. Eur J Cancer. 1993; 29A Suppl 5:S9-13.
    View in: PubMed
    Score: 0.001
  129. Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer. Cancer. 1991 Sep 01; 68(5):959-64.
    View in: PubMed
    Score: 0.001
  130. Ifosfamide with mesna uroprotection in the management of lung cancer. Am J Clin Oncol. 1990 Apr; 13(2):148-55.
    View in: PubMed
    Score: 0.001
  131. The role of adjuvant surgery in the combined modality therapy of small-cell bronchogenic carcinoma after a chemotherapy-induced partial remission. J Clin Oncol. 1990 Mar; 8(3):416-22.
    View in: PubMed
    Score: 0.001
  132. Primary chemotherapy of brain metastasis in small-cell lung cancer. J Clin Oncol. 1989 Jul; 7(7):916-22.
    View in: PubMed
    Score: 0.001
  133. Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma. Invest New Drugs. 1988 Sep; 6(3):217-8.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.